Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.
Latest Information Update: 23 Feb 2022
Price :
$35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 01 Oct 2020 Primary endpoint has not been met. (Event-free survival (clinical progression, biochemical progression, death) at 5 years)
- 01 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 01 Oct 2020 Results published in the Lancet Oncology